Finance
GSK Agrees to Buy Nuvalent for $10.6 Billion
Image via Bloomberg
Article Summary
83 words
GSK agreed to buy Nuvalent in a deal valued at $10.6 billion, adding a biotech firm that’s developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise. Sam Fazeli of Bloomberg Intelligence has more.… GSK agreed to buy Nuvalent in a deal valued at $10.6 billion, adding a biotech firm that’s developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise. Sam Fazeli of Bloomberg Intelligence has more. (Source: Bloomberg)
Continue Reading
Full story on Bloomberg
🔗 Clicking will take you to www.bloomberg.com



